Bristol-Myers Squibb and Incyte just entered an agreement to evaluate the safety, tolerability, and preliminary efficacy of a combination regimen consisting of Bristol-Myers’ nivolumab and Incyte’s INCB24360 for multiple tumor types.
Nivolumab is a PD-1 immune checkpoint inhibitor, a...
Tuesday"s Top Health Care Stories: BioCryst, Durata, Bristol-Myers Squibb, and ...
Tuesday, May 27, 2014
Tuesday"s Top Health Care Stories: BioCryst, Durata, Bristol-Myers Squibb, and ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment